NEXCEDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nexcede, and when can generic versions of Nexcede launch?
Nexcede is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in NEXCEDE is ketoprofen. There are twenty-seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ketoprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nexcede
A generic version of NEXCEDE was approved as ketoprofen by TEVA on December 22nd, 1992.
Summary for NEXCEDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 164 |
Clinical Trials: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NEXCEDE at DailyMed |
Recent Clinical Trials for NEXCEDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Rochester | Phase 2/Phase 3 |
Mae Stone Goode Foundation | Phase 2/Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for NEXCEDE
US Patents and Regulatory Information for NEXCEDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | NEXCEDE | ketoprofen | FILM;ORAL | 022470-001 | Nov 25, 2009 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |